Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368(25):2402–14.
Selvaskandan H, Shi S, Twaij S, Cheung CK, Barratt J. Monitoring Immune responses in IgA Nephropathy: biomarkers to Guide Management. Front Immunol. 2020;11:572754.
Maixnerova D, Reily C, Bian Q, Neprasova M, Novak J, Tesar V. Markers for the progression of IgA nephropathy. J Nephrol. 2016;29(4):535–41.
Kaartinen K, Syrjänen J, Pörsti I, Hurme M, Harmoinen A, Pasternack A, Huhtala H, Mustonen J. Inflammatory markers and the progression of IgA glomerulonephritis. Nephrol Dial Transpl. 2008;23(4):1285–90.
Williams CEC, Toner A, Wright RD, Oni L. A systematic review of urine biomarkers in children with IgA vasculitis nephritis. Pediatr Nephrol. 2021;36(10):3033–44.
Zhao W, Feng S, Wang Y, Wang C, Ren P, Zhang J, Yu L, Zhang C, Bai L, Chen Y, et al. Elevated urinary IL-6 predicts the progression of IgA Nephropathy. Kidney International Reports; 2022.
Moresco RN, Speeckaert MM, Delanghe JR. Diagnosis and monitoring of IgA nephropathy: the role of biomarkers as an alternative to renal biopsy. Autoimmun rev. 2015;14(10):847–53.
Harada K, Akai Y, Kurumatani N, Iwano M, Saito Y. Prognostic value of urinary interleukin 6 in patients with IgA nephropathy: an 8-year follow-up study. Nephron. 2002;92(4):824–6.
Barbour SJ, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, Katafuchi R, Er L, Espino-Hernandez G, Kim SJ, et al. Evaluating a New International Risk-Prediction Tool in IgA Nephropathy. JAMA Intern Med. 2019;179(7):942–52.
Matsushita K, Mahmoodi BK, Woodward M, Emberson JR, Jafar TH, Jee SH, Polkinghorne KR, Shankar A, Smith DH, Tonelli M. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA. 2012;307(18):1941–51.
Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, Liu ZH, Roberts IS, Yuzawa Y, Zhang H, et al. Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification Working Group. Kidney Int. 2017;91(5):1014–21.
Gao J, Wei L, Liu X, Wang L, Niu D, Jin T, Yao G, Wang M, Yu Q, Fu R. Association between IFN-γ gene polymorphisms and IgA nephropathy in a Chinese Han Population. Kidney Blood Press Res. 2017;42(1):136–44.
Horii Y, Iwano M, Hirata E, Shiiki M, Fujii Y, Dohi K, Ishikawa H. Role of interleukin-6 in the progression of mesangial proliferative glomerulonephritis. Kidney Int Suppl. 1993;39:S71–75.
Lv LL, Feng Y, Wen Y, Wu WJ, Ni HF, Li ZL, Zhou LT, Wang B, Zhang JD, Crowley SD, et al. Exosomal CCL2 from tubular epithelial cells is critical for Albumin-Induced Tubulointerstitial inflammation. J Am Soc Nephrol. 2018;29(3):919–35.
Ranieri E, Gesualdo L, Petrarulo F, Schena FP. Urinary IL-6/EGF ratio: a useful prognostic marker for the progression of renal damage in IgA nephropathy. Kidney Int. 1996;50(6):1990–2001.
Samouilidou E, Athanasiadou V, Grapsa E. Prognostic and Diagnostic Value of Endocan in Kidney Diseases. Int J Nephrol 2022, 2022:3861092.
Krensky AM, Ahn YT. Mechanisms of disease: regulation of RANTES (CCL5) in renal disease. Nat Clin Pract Nephrol. 2007;3(3):164–70.
Masutani K, Miyake K, Nakashima H, Hirano T, Kubo M, Hirakawa M, Tsuruya K, Fukuda K, Kanai H, Otsuka T, et al. Impact of interferon-gamma and interleukin-4 gene polymorphisms on development and progression of IgA nephropathy in Japanese patients. Am J Kidney Dis. 2003;41(2):371–9.
Saitoh A, Suzuki Y, Takeda M, Kubota K, Itoh K, Tomino Y. Urinary levels of monocyte chemoattractant protein (MCP)-1 and disease activity in patients with IgA nephropathy. J Clin Lab Anal. 1998;12(1):1–5.
<a data-track="click" rel="nofollow noopener" data-track-label="10.1002/(SICI)1098-2825(1998)12:13.0.CO;2-F” data-track-action=”article reference” href=”https://doi.org/10.1002%2F%28SICI%291098-2825%281998%2912%3A1%3C1%3A%3AAID-JCLA1%3E3.0.CO%3B2-F” aria-label=”Article reference 19″ data-doi=”10.1002/(SICI)1098-2825(1998)12:13.0.CO;2-F”>Article
CAS
PubMed
PubMed Central
Google Scholar
Luo R, Yang Y, Cheng Y-C, Chang D, Liu T-T, Li Y-Q, Dai W, Zuo M-Y, Xu Y-L, Zhang C-X, et al. Plasma chemokine CXC motif-ligand 16 as a predictor of renal prognosis in immunoglobulin A nephropathy. Annals Translational Med. 2020;8(6):381.
Cao Y, Lu G, Chen X, Chen X, Guo N, Li W. BAFF is involved in the pathogenesis of IgA nephropathy by activating the TRAF6/NF–κB signaling pathway in glomerular mesangial cells. Mol Med Rep. 2020;21(2):795–805.
Zheng N, Wang B, Fan J, Luo N, Kong Q, Ye H, Zhang J, Ming H, Yu X. Increased abundance of Plasmacytoid dendritic cells and Interferon-Alpha induces plasma cell differentiation in patients of IgA Nephropathy. Mediators Inflamm. 2017;2017:4532409.
Na KR, Kim YH, Chung HK, Yeo MK, Ham YR, Jeong JY, Kim KS, Lee KW, Choi DE. Growth differentiation factor 15 as a predictor of adverse renal outcomes in patients with immunoglobulin A nephropathy. Intern Med J. 2017;47(12):1393–9.
Torres DD, Rossini M, Manno C, Mattace-Raso F, D’Altri C, Ranieri E, Pontrelli P, Grandaliano G, Gesualdo L, Schena FP. The ratio of epidermal growth factor to monocyte chemotactic peptide-1 in the urine predicts renal prognosis in IgA nephropathy. Kidney Int. 2008;73(3):327–33.
Zhang Y, Nakano D, Guan Y, Hitomi H, Uemura A, Masaki T, Kobara H, Sugaya T, Nishiyama A. A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice. Kidney Int. 2018;94(3):524–35.
Bargenda A, Musiał K, Zwolińska D. Epidermal growth factor, growth differentiation factor-15, and survivin as novel biocompatibility markers in children on chronic dialysis. Biomarkers. 2016;21(8):752–6.
Kleinertz H, Hepner-Schefczyk M, Ehnert S, Claus M, Halbgebauer R, Boller L, Huber-Lang M, Cinelli P, Kirschning C, Flohé S, et al. Circulating growth/differentiation factor 15 is associated with human CD56(bright) natural killer cell dysfunction and nosocomial infection in severe systemic inflammation. EBioMedicine. 2019;43:380–91.
Siddiqui K, Joy SS, Al-Rubeaan K. Association of urinary monocyte chemoattractant protein-1 (MCP-1) and kidney injury molecule-1 (KIM-1) with risk factors of diabetic kidney disease in type 2 diabetes patients. Int Urol Nephrol. 2019;51(8):1379–86.
Nair V, Robinson-Cohen C, Smith MR, Bellovich KA, Bhat ZY, Bobadilla M, Brosius F, de Boer IH, Essioux L, Formentini I, et al. Growth differentiation Factor-15 and risk of CKD progression. J Am Soc Nephrol. 2017;28(7):2233–40.
Kim JS, Kim S, Won CW, Jeong KH. Association between plasma levels of growth differentiation Factor-15 and renal function in the Elderly: Korean Frailty and Aging Cohort Study. Kidney Blood Press Res. 2019;44(3):405–14.
Perez-Gomez MV, Pizarro-Sanchez S, Gracia-Iguacel C, Cano S, Cannata-Ortiz P, Sanchez-Rodriguez J, Sanz AB, Sanchez-Nino MD, Ortiz A. Urinary growth differentiation Factor-15 (GDF15) levels as a biomarker of adverse outcomes and biopsy findings in chronic kidney disease. J Nephrol. 2021;34(6):1819–32.
Bagchi S, Lingaiah R, Mani K, Barwad A, Singh G, Balooni V, Bhowmik D, Agarwal SK. Significance of serum galactose deficient IgA1 as a potential biomarker for IgA nephropathy: a case control study. PLoS ONE. 2019;14(3):e0214256.
Rops A, Jansen E, van der Schaaf A, Pieterse E, Rother N, Hofstra J, Dijkman H, van de Logt AE, Wetzels J, van der Vlag J, et al. Interleukin-6 is essential for glomerular immunoglobulin a deposition and the development of renal pathology in Cd37-deficient mice. Kidney Int. 2018;93(6):1356–66.
Gesualdo L, Paolo SD, Calabró A, Milani S, Maiorano E, Ranieri E, Pannarale G, Schena FP. Expression of epidermal growth factor and its receptor in normal and diseased human kidney: an immunohistochemical and in situ hybridization study. Kidney Int. 1996;49(3):656–65.
Segarra-Medrano A, Carnicer-Caceres C, Valtierra-Carmeno N, Agraz-Pamplona I, Ramos-Terrades N, Jatem Escalante E, Ostos-Roldan E. Value of urinary levels of interleukin-6, epidermal growth factor, monocyte chemoattractant protein type1 and transforming growth factor β1 in predicting the extent of fibrosis lesions in kidney biopsies of patients with IgA nephropathy. Nefrologia. 2017;37(5):531–8.
Stangou M, Alexopoulos E, Papagianni A, Pantzaki A, Bantis C, Dovas S, Economidou D, Leontsini M, Memmos D. Urinary levels of epidermal growth factor, interleukin-6 and monocyte chemoattractant protein-1 may act as predictor markers of renal function outcome in immunoglobulin A nephropathy. Nephrol (Carlton). 2009;14(6):613–20.
- The Renal Warrior Project. Join Now
- Source: https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-024-03574-2